uep_logo
Strada delle Scotte, 6 53100 Siena
tel 0577 233228
info@insostanza.it

Sei in:

Cannabidiolo e ricadute

Uno studio su animali ha scoperto che il cannabidiolo (CBD), una sostanza chimica non psicoattiva presente nella marijuana, puA? aiutare a ridurre il rischio di ricaduta da droga e alcol.
I ricercatori hanno applicato, ogni giorno per una settimana, un gel contenente cannabidiolo sulla pelle di ratti con una storia di auto-somministrazione giornaliera di alcol o cocaina. La sostanza A? apparsa essere in grado di ridurre efficacemente il ripristino all’assunzione di droghe, comportamento considerato un modello di ricaduta. Il cannabidiolo alla stesso tempo riduceva anche l’ansia e l’impulsivitA�, spesso associate ad un quadro di tossicodipendenza.
In particolare, la mancanza di ricaduta (di riassunzione di sostanza), indotta dallo stress o da fattori ambientali legati alla droga, A? durata cinque mesi dopo l’interruzione del trattamento iniziale quando cioA? il CBD non A? piA? rilevabile nel sangue o nel cervello.
Il cannabidiolo A? stato frequentemente studiato come possibile trattamento in alcune gravi sindromi di epilessia infantile. Questi risultati rafforzano altri possibili benefici terapeutici dei cannabinoidi non psicoattivi, se pure gli autori sottolineano la necessitA� di ulteriori ricerche sull’uso di questo a�?farmacoa�? per la prevenzione delle ricadute.
La ricerca, condotta dallo Scripps Research Institute, A? stata finanziata dal National Institute on Drug Abuse (NIDA) e the National Institute on Alcohol Abuse and Alcoholism, entrambi parte del National Institutes of Health.

montefrancesco
Fonte NIDA

Lavoro originale: Gustavo Gonzalez-Cuevas et al, Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle, Neuropsychopharmacology (2018), doi:10.1038/s41386-018-0050-8, 22 March 2018

Abstract
Cannabidiol (CBD), the major non-psychoactive constituent of Cannabis sativa, has received attention for therapeutic potential in treating neurologic and psychiatric disorders.
Recently, CBD has also been explored for potential in treating drug addiction. Substance use disorders are chronically relapsing conditions and relapse risk persists for multiple reasons including craving induced by drug contexts, susceptibility to stress, elevated anxiety, and impaired impulse control. Here, we evaluated the a�?anti-relapsea�? potential of a transdermal CBD preparation in animal models of drug seeking, anxiety and impulsivity. Rats with alcohol or cocaine self-administration histories received transdermal CBD at 24a��h intervals for 7 days and were tested for context and stress-induced reinstatement, as well as experimental anxiety on the elevated plus maze.
Effects on impulsive behavior were established using a delay-discounting task following recovery from a 7-day dependence-inducing alcohol intoxication regimen. CBD attenuated context-induced and stress-induced drug seeking without tolerance, sedative effects, or interference with normal motivated behavior. Following treatment termination, reinstatement remained attenuated up to a�?5 months although plasma and brain CBD levels remained detectable only for 3 days.
CBD also reduced experimental anxiety and prevented the development of high impulsivity in rats with an alcohol dependence history.
The results provide proof of principle supporting potential of CBD in relapse prevention along two dimensions CBD:
beneficial actions across several vulnerability states,
and long-lasting effects with only brief treatment.
The findings also inform the ongoing medical marijuana debate concerning medical benefits of non-psychoactive cannabinoids and their promise for development and use as therapeutics.

 

tags: #cannabidiolo e ricadute

I commenti sono chiusi.

 

European Drug Report 2018: Trends and Developments.

High availability of drugs across all types. Over 1 million seizures in Europe in 2016. Over 92 million adults in the EU have tried an illicit drug in their lifetime. 1.3 million people received treatment for illicit drugs. Cocaine purity at street level reached its highest level in a decade. Increase in number of cocaine seizures. Increase in cocaine residues in wastewater in 26 of 31 cities between 2015 and 2017. Rise in number of first-time admissions to specialised treatment for problems related to cocaine. Europe is an important market for drugs trafficked in from other regions. But there are worrying signs of increased drug production inside Europe. Cannabis availability and use remain high. Cannabis is involved in 77 % of drug law offences. Rapid emergence of a commercial cannabis market in parts of the Americas. Fewer new psychoactive substances reported for the first time. But there is more evidence of harm. Health harms linked to highly potent new synthetic cannabinoids and synthetic opioids prompted nine risk assessments. Synthetic cannabinoids are the most frequently seized NPS in Europe. Synthetic opioids and particularly fentanyl derivatives are increasingly detected. Fentanyl derivatives — key players in the US opioid crisis — call for concern & vigilance. NPS use and related harms are a new challenge for prison system. Prisons are a critical setting for addressing the healthcare needs of drug users. Online markets appear to be of growing importance. A recent EMCDDA–Europol study identified more than 100 darknet markets. Concerns over unlicensed benzodiazepines sold on the street and online. Increasing number of overdose deaths raises concerns. Renewed focus on the role of take-home naloxone in overdose response strategies. Read more in the European Drug Report 2018: emcdda.europa.eu/edr2018

LE CREAZIONI DI INSOSTANZA